Eli Lilly's Zepbound has become the first drug to be FDA-approved for obstructive sleep apnoea (OSA), a sleep-related ...

Zepbound, from drugmaker Eli Lilly, is already approved for people who are obese or overweight and have a related health condition, such as type 2 diabetes, high cholesterol or high blood ...

First UK patients describe receiving the technology which could spell the end for the uncomfortable masks some sufferers have ...

Sleep apnoea sufferers have been given a new lease of life with an app-controlled device that stimulates the nerves in the ...

The procedure to fit the Genio Nyxoah implant was carried out at University College London Hospitals NHS Foundation Trust ...

Acurable’s AcuPebble became the first device to receive a CE mark for fully automated obstructive sleep apnoea diagnosis.

FDA approves Zepbound for sleep apnoea, a weight-loss medication that improves OSA symptoms in obese patients.

The technology, which is a first in Britain, could spell the end for uncomfortable machinery which some people need to sleep ...

It’s claimed to help with snoring and sleep apnoea, and there is anecdotal evidence that inhaling through the nose is better ...

A grandmother who has suffered from sleep apnoea for a decade has been fitted with a groundbreaking piece of tech to tackle ...

The battery-free, single-incision, and leadless system represents a solution for adults suffering from moderate to severe OSA ...

A new treatment in which surgeons implant a chip on a critical nerve could mean relief for the eight million people in the UK ...